Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
HC Wainwright initiated coverage on Gyre Therapeutics, rating it 'Buy'. Gyre missed Q2 revenue expectations, reporting $26.78 million against $30.8 million. Hydronidone shows promise in Phase 3 trials for liver fibrosis with significant results. Expected revenue growth of 11.3% to 20.8% in 2025 driven by new therapies. Analysts forecast Hydronidone could reach $6 billion in annual U.S. sales by 2033.
View signal analysis